TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Genedrive ( (GB:GDR) ).
Genedrive plc has released its 2025 Annual Report and Accounts, now accessible on their website, with the Annual General Meeting scheduled for 31 December 2025. The company continues to focus on growth through market expansion and strategic acquisitions, leveraging its innovative pharmacogenetic testing products, which are gaining traction in the healthcare industry.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Spark’s Take on GB:GDR Stock
According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.
Genedrive is navigating profitability challenges despite strong revenue growth and a solid balance sheet. Technical analysis indicates bearish momentum, while valuation metrics are unappealing due to lack of profitability. However, recent corporate developments are promising, potentially enhancing market positioning and future prospects.
To see Spark’s full report on GB:GDR stock, click here.
More about Genedrive
Genedrive plc is a UK-based company specializing in pharmacogenetic testing, focusing on developing and commercializing rapid, cost-effective, and easy-to-use point-of-care platforms for diagnosing genetic variants. Their flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, are designed to aid clinicians in making informed decisions on medication use, particularly in emergency healthcare settings. These products are recognized by the UK NHS and have been recommended by NICE.
Average Trading Volume: 57,518,979
Technical Sentiment Signal: Sell
Current Market Cap: £10.3M
For an in-depth examination of GDR stock, go to TipRanks’ Overview page.